	US 12,304,946 B2
	Antibodies that neutralize hepatitis B virus and uses thereof
Davide Corti, Bellinzona (CH)
Assigned to Humabs BioMed SA, Bellinzona (CH)
Appl. No. 17/413,696
Filed by HUMABS BIOMED SA, Bellinzona (CH)
PCT Filed Dec. 18, 2019, PCT No. PCT/US2019/067216 § 371(c)(1), (2) Date Jun. 14, 2021, PCT Pub. No. WO2020/132091, PCT Pub. Date Jun. 25, 2020.
Claims priority of provisional application 62/860,085, filed on Jun. 11, 2019.
Claims priority of provisional application 62/782,274, filed on Dec. 19, 2018.
Prior Publication US 2022/0127336 A1, Apr. 28, 2022
Int. Cl. C07K 16/08 (2006.01); A61K 31/522 (2006.01); A61K 39/42 (2006.01); C07K 16/10 (2006.01); G01N 33/569 (2006.01)

CPC C07K 16/082 (2013.01) [A61K 31/522 (2013.01); A61K 39/42 (2013.01); C07K 16/10 (2013.01); G01N 33/56983 (2013.01); C07K 2317/732 (2013.01); C07K 2317/76 (2013.01); G01N 2333/02 (2013.01); G01N 2800/26 (2013.01)]

28 Claims

1. An isolated antibody that binds HBsAg comprising:

(i) a heavy chain (HC) comprising the amino acid sequence according to SEQ ID NO: 91; and

(ii) a light chain (LC) comprising the amino acid sequence according to SEQ ID NO: 93.